Group 1 - China Tongru (01763) has seen its stock price increase by over 130% year-to-date, with a recent rise of 7.94% to HKD 24.48, and a trading volume of HKD 13.03 million [1] - On November 5, Novartis announced that its radioligand therapy (RLT) drug Pluvicto received approval from the National Medical Products Administration for two indications, which is expected to boost the domestic nuclear medicine industry [1] - Ping An Securities highlighted that the approval of Pluvicto may further ignite interest in the domestic nuclear medicine sector, suggesting to pay attention to companies like China Tongru that are leading in new isotopes and targets [1] Group 2 - On October 31, China Tongru announced the launch of carbon isotope products, marking a significant breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials [1] - The company has become a leading enterprise that fully masters the entire industry chain of breath test products and has officially initiated the construction of the second phase of its stable isotope base project [1]
中国同辐再涨超8% 诺华核药在华获批上市 有望点燃国内核医学行业热度